Communicating Benefits from Vaccines Beyond Preventing Infectious Diseases

被引:16
作者
Chevalier-Cottin, Emma-Pascale [1 ]
Ashbaugh, Hayley [2 ]
Brooke, Nicholas [3 ]
Gavazzi, Gaetan [4 ]
Santillana, Mauricio [5 ]
Burlet, Nansa [6 ]
Tin Tin Htar, Myint [7 ]
机构
[1] Sanofi Pasteur, Lyon, France
[2] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA
[3] Synergist Org, Brussels, Belgium
[4] Grenoble Alpes Univ, Geriatr Clin, Grenoble Alpes Univ Hosp, GREPI EA, F-7408 Grenoble, France
[5] Harvard Med Sch, Boston Childrens Hosp, Boston, MA 02115 USA
[6] Sanofi Pasteur, Global Head Patient Insights Innovat, Lyon, France
[7] Pfizer Inc, Med Dev & Sci Clin Affairs, Paris, France
关键词
Communication; Direct benefits; Indirect benefits; Vaccination; Vaccines; PNEUMOCOCCAL CONJUGATE VACCINE; MEASLES-VIRUS INFECTION; UNITED-STATES; INFLUENZA; IMMUNIZATION; IMPACT; COMPLETION; PNEUMONIA; CHILDREN; MEDIA;
D O I
10.1007/s40121-020-00312-7
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Despite immunisation being one of the greatest medical success stories of the twentieth century, there is a growing lack of confidence in some vaccines. Improving communication about the direct benefits of vaccination as well as its benefits beyond preventing infectious diseases may help regain this lost confidence. A conference was organised at the Fondation Merieux in France to discuss what benefits could be communicated and how innovative digital initiatives can used for communication. During this meeting, a wide range of indirect benefits of vaccination were discussed. For example, influenza vaccination can reduce hospitalisations and deaths in older persons with diabetes by 45% and 38%, respectively, but the link between influenza and complications from underlying chronic non-communicable diseases such as diabetes is frequently underestimated. Vaccination can reduce antimicrobial resistance (AMR), which is growing, by reducing the incidence of infectious disease (though direct and indirect or herd protection), by reducing the number of circulating AMR strains, and by reducing the need for antimicrobial use. Disease morbidity and treatment costs in the elderly population are likely to rise substantially, with the ageing global population. Healthy ageing and life-course vaccination approaches can reduce the burden of vaccine-preventable diseases, such as seasonal influenza and pneumococcal diseases, which place a significant burden on individuals and society, while improving quality of life. Novel disease surveillance systems based on information from Internet search engines, mobile phone apps, social media, cloud-based electronic health records, and crowd-sourced systems, contribute to improved awareness of disease burden. Examples of the role of new techniques and tools to process data generated by multiple sources, such as artificial intelligence, to support vaccination programmes, such as influenza and dengue, were discussed. The conference participants agreed that continual efforts are needed from all stakeholders to ensure effective, transparent communication of the full benefits and risks of vaccination.
引用
收藏
页码:467 / 480
页数:14
相关论文
共 69 条
  • [1] Vaccination greatly reduces disease, disability, death and inequity worldwide
    Andre, F. E.
    Booy, R.
    Bock, H. L.
    Clemens, J.
    Datta, S. K.
    John, T. J.
    Lee, B. W.
    Lolekha, S.
    Peltola, H.
    Ruff, T. A.
    Santosham, M.
    Schmitt, H. J.
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2008, 86 (02) : 140 - 146
  • [2] Vaccine Evolution and Its Application to Fight Modern Threats
    Andreano, Emanuele
    D'Oro, Ugo
    Rappuoli, Rino
    Finco, Oretta
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10 : 1722
  • [3] Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications
    Andrew, Melissa K.
    Bowles, Susan K.
    Pawelec, Graham
    Haynes, Laura
    Kuchel, George A.
    McNeil, Shelly A.
    McElhaney, Janet E.
    [J]. DRUGS & AGING, 2019, 36 (01) : 29 - 37
  • [4] Association of Previous Measles Infection With Markers of Acute Infectious Disease Among 9-to 59-Month-Old Children in the Democratic Republic of the Congo
    Ashbaugh, Hayley R.
    Cherry, James D.
    Hoff, Nicole A.
    Doshi, Reena H.
    Alfonso, Vivian H.
    Gadoth, Adva
    Mukadi, Patrick
    Higgins, Stephen G.
    Budd, Roger
    Randall, Christina
    Okitolonda-Wemakoy, Emile
    Muyembe-Tamfum, Jean Jacques
    Gerber, Sue K.
    Rimoin, Anne W.
    [J]. JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2019, 8 (06) : 531 - 538
  • [5] Vaccine acceptance: Science, policy, and practice in a 'post-fact' world
    Attwell, Katie
    Dube, Eve
    Gagneur, Arnaud
    Omer, Saad B.
    Suggs, L. Suzanne
    Thomson, Angus
    [J]. VACCINE, 2019, 37 (05) : 677 - 682
  • [6] CIOMS Guide To Vaccine Safety Communication - Executive summary
    Bahri, Priya
    Rago, Lembit
    Abdoellah, Siti Asfijah
    Bachtiar, Novilia Working
    Bahri, Priya
    Balakrishnan, Madhav Ram
    Bergman, Ulf
    Chandler, Rebecca
    Chua, Peter Glen
    Darko, Mimi Delese
    Dodoo, Alexander
    Habersaat, Katrine Bach
    Hartigan-Go, Ken
    Hugman, Bruce
    Lindquist, Marie
    Santos, Paulo
    Zuber, Patrick
    [J]. VACCINE, 2019, 37 (03) : 401 - 408
  • [7] Listen to the public and fulfil their information interests - translating vaccine communication research findings into guidance for regulators
    Bahri, Priya
    Melero, Mireia Castillon
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (08) : 1696 - 1705
  • [8] Belamarich P R, 1998, Pediatr Rev, V19, P70, DOI 10.1542/pir.19-2-70
  • [9] Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines
    Black, Steven
    Eskola, Juhani
    Siegrist, Claire-Anne
    Halsey, Neal
    MacDonald, Noni
    Law, Barbara
    Miller, Elizabeth
    Andrews, Nick
    Stowe, Julia
    Salmon, Daniel
    Vannice, Kirsten
    Izurieta, Hector S.
    Akhtar, Aysha
    Gold, Mike
    Oselka, Gabriel
    Zuber, Patrick
    Pfeifer, Dina
    Vellozzi, Claudia
    [J]. LANCET, 2009, 374 (9707) : 2115 - 2122
  • [10] A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France
    Bresse, Xavier
    Adam, Marjorie
    Largeron, Nathalie
    Roze, Stephane
    Marty, Remi
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (04) : 823 - 833